Medicare Enrolled
Dr. Jasmin Desai, M.D.
Hematology · Brooksville, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Desai from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Desai? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Desai
Dr. Jasmin Desai is a hematology in Brooksville, FL, with 13 years in practice. Based on federal Medicare data, Dr. Desai performed 45,161 Medicare services across 1,748 unique beneficiaries.
Between the years covered by Open Payments, Dr. Desai received a total of $6,095 from 72 pharmaceutical and/or device companies across 313 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Desai is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice▲ 45,161 Medicare services$ $6,095 industry payments
Medicare Practice Summary
Medicare Utilization ↗45,161
Medicare services
Bottom 35% in FL for hematology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
1,748
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,474 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 33,000 | $0 | $5 |
| Anti-nausea injection (aprepitant) | 4,680 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 1,620 | $18 | $51 |
| Dexamethasone injection (steroid) | 856 | $0 | $3 |
| Epoetin alfa injection (Procrit) for anemia | 760 | $6 | $23 |
| Complete blood count (CBC) with differential | 603 | $8 | $29 |
| Blood draw (venipuncture) | 579 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 530 | $1 | $28 |
| Drug injection, under skin or into muscle | 391 | $10 | $69 |
| Anti-nausea injection (ondansetron/Zofran) | 340 | $0 | $9 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 267 | $1 | $6 |
| Office visit, established patient (30-39 min) | 185 | $93 | $339 |
| Office visit, established patient (20-29 min) | 184 | $61 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 168 | $47 | $189 |
| Injection of additional new drug or substance into vein | 134 | $11 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 110 | $96 | $378 |
| Injection of drug or substance into vein | 96 | $27 | $156 |
| Injection, zoledronic acid, 1 mg | 90 | $7 | $69 |
| Infusion into a vein for hydration, each additional hour | 83 | $9 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 79 | $22 | $84 |
| Infusion, normal saline solution , 1000 cc | 49 | $2 | $7 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 43 | $18 | $59 |
| New patient office visit (45-59 min) | 40 | $122 | $453 |
| Office visit, established patient, complex (40-54 min) | 40 | $131 | $474 |
| Infusion into a vein for hydration, 31-60 minutes | 37 | $22 | $156 |
| Injection, diphenhydramine hcl, up to 50 mg | 32 | $1 | $3 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $49 | $178 |
| Automated urinalysis | 25 | $2 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $16 | $56 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $1 | $7 |
| Initial hospital admission, moderate complexity | 18 | $103 | $377 |
| Red blood count automated, with additional calculations | 17 | $5 | $20 |
| Initial hospital admission, high complexity | 17 | $114 | $556 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 15 | $3 | $11 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.0% high complexity
95.0% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,095
Total received (2018-2024)
Avg $871/year across 7 years
Bottom 44% in FL for hematology
72
Companies
313
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,095 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,989
2023$1,695
2022$1,051
2021$559
2020$639
2019$28
2018$133
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$538
PFIZER INC.
$352
Celgene Corporation
$343
Merck Sharp & Dohme LLC
$236
Gilead Sciences, Inc.
$208
Janssen Biotech, Inc.
$202
Seagen Inc.
$199
Incyte Corporation
$183
E.R. Squibb & Sons, L.L.C.
$182
Eisai Inc.
$179
GENZYME CORPORATION
$179
AstraZeneca Pharmaceuticals LP
$159
Lilly USA, LLC
$159
EMD Serono, Inc.
$154
Genentech USA, Inc.
$140
Daiichi Sankyo Inc.
$135
Tempus AI, Inc
$127
Karyopharm Therapeutics Inc.
$121
GlaxoSmithKline, LLC.
$114
Merck Sharp & Dohme Corporation
$108
Astellas Pharma US Inc
$106
Amgen Inc.
$100
Rigel Pharmaceuticals, Inc.
$100
Ipsen Biopharmaceuticals, Inc
$92
PORTOLA PHARMACEUTICALS, INC.
$89
Regeneron Healthcare Solutions, Inc.
$85
ARRAY BIOPHARMA INC
$85
Kite Pharma, Inc.
$85
Stemline Therapeutics Inc.
$81
Boehringer Ingelheim Pharmaceuticals, Inc.
$76
Octapharma USA, Inc.
$68
Pharmacyclics LLC, An AbbVie Company
$62
EISAI INC.
$60
Agios Pharmaceuticals, Inc.
$57
Fennec Pharmaceuticals, Inc.
$52
Mirati Therapeutics, Inc.
$49
Dova Pharmaceuticals
$39
Myriad Genetic Laboratories, Inc.
$37
Sobi, Inc
$36
AVEO Pharmaceuticals, Inc.
$36
PUMA BIOTECHNOLOGY, INC.
$35
G1 Therapeutics, Inc.
$34
Takeda Pharmaceuticals U.S.A., Inc.
$33
Medtronic, Inc.
$33
CTI BioPharma Corp.
$30
BeiGene USA, Inc.
$27
SpringWorks Therapeutics, Inc.
$26
Axonics, Inc.
$24
Bayer Healthcare Pharmaceuticals Inc.
$24
GE HealthCare
$23
Azurity Pharmaceuticals, Inc.
$23
Adaptive Biotechnologies Corporation
$22
Exelixis Inc.
$21
CSL Behring
$21
Pharmacosmos Therapeutics Inc.
$19
MorphoSys, US Inc.
$19
Jazz Pharmaceuticals Inc.
$19
SOBI, INC
$19
Deciphera Pharmaceuticals Inc.
$19
ABBVIE INC.
$18
Sumitomo Pharma America, Inc.
$17
MACROGENICS, INC.
$17
Alnylam Pharmaceuticals Inc.
$17
Myovant Sciences Inc.
$17
TAIHO ONCOLOGY, INC.
$16
Puma Biotechnology, Inc.
$16
Heron Therapeutics, Inc.
$16
Bayer HealthCare Pharmaceuticals Inc.
$15
SUN PHARMACEUTICAL INDUSTRIES INC.
$15
Clovis Oncology, Inc.
$15
NOVARTIS PHARMACEUTICALS CORPORATION
$15
Kyowa Kirin, Inc.
$14
Top 3 companies account for 20.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · ANDEXXA · AUGTYRO · Alecensa · Avastin · Axonics r-SNM System · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CALQUENCE · CINVANTI · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELREXFIO · ENHERTU · ENJAYMO · Enhertu · FOTIVDA · FRUZAQLA · Fabhalta · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · INTELLIS ADAPTIVESTIM · Idelvion · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MARGENZA · MEKINIST · MONJUVI · MYRISK · NERLYNX · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PLUVICTO · POLIVY · PROMACTA · Padcev · Pedmark · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Rezlidhia · Rubraca · SARCLISA · SOMATULINE DEPOT · Stivarga · TABRECTA · TAGRISSO · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Trodelvy · VERZENIO · VIVIMUSTA · VOTRIENT · Vanflyta · Venclexta · Vonjo · XALKORI · XGEVA · XPOVIO · XT CDX · XTANDI · Xospata · YONSA · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $14 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
11
Per 100K population
5.5
County median income
$63,193
Nearest hospital
HCA FLORIDA OAK HILL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Desai is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Desai experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Desai performed 33,000 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Desai receive payments from pharmaceutical companies?
Yes. Dr. Desai received a total of $6,095 from 72 companies across 313 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Desai's costs compare to other hematologys in Brooksville?
Dr. Desai's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Desai) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Brooksville
Browse hematologys in Brooksville ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology